Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Physiological and metabolic response of crab megalopae and juveniles to ocean acidification (part-III) (Study ST001165)

Reversed phase POSITIVE ION MODE (Analysis AN001926)

Metabolite	Structure	F1	F2	F3	F4
SM (d36:2)	ME277519	1.64	0.79	0.78	0.79
SM (d38:2)	ME277521	2.02	0.65	0.67	0.67
Gal-Gal-Cer(d18:1/16:0) or Lactosylceramide(d18:1/16:0)	ME277462	0.76	0.68	0.64	1.91
LPC (22:6)	ME277472	0.69	0.70	0.85	1.76
LPC (20:4)	ME277470	0.82	0.72	1.02	1.44
PC (34:4)	ME277480	0.59	1.05	0.79	1.56
PC (38:7)	ME277495	0.67	1.00	0.81	1.53
PC (36:5) A	ME277485	0.66	1.05	0.83	1.46
PC (36:6)	ME277487	0.64	1.02	0.84	1.50
PC (28:0)	ME277473	0.63	1.05	0.81	1.50
PC (30:1)	ME277475	0.61	1.06	0.81	1.52
LPC (20:5)	ME277471	0.77	0.85	0.85	1.52
PC (37:6)	ME277489	0.64	0.94	0.88	1.54
PC (36:5) B	ME277486	0.68	0.97	0.86	1.49
PC 42:11; PC(20:5/22:6);	ME277508	0.72	0.93	0.84	1.51
PC (34:3)	ME277479	0.71	0.88	0.93	1.48
PC (35:4)	ME277482	0.67	0.95	0.94	1.44
PC (p-38:5) or PC (o-38:6)	ME277503	0.73	0.94	0.90	1.44
PC (36:3) B	ME277483	0.90	0.95	0.91	1.24
LPC (14:0)	ME277463	0.86	0.94	0.98	1.22
LPC (15:0)	ME277464	0.81	0.95	0.97	1.26
LPC (16:1)	ME277466	0.88	0.82	0.92	1.39
LPC (16:0)	ME277465	0.82	0.87	0.97	1.33
LPC (20:3)	ME277469	0.83	0.87	0.97	1.33
PE (p-36:4) or PE (o-36:5)	ME277512	0.88	1.08	0.85	1.19
PE (p-38:5) or PE (o-38:6)	ME277514	0.87	1.06	0.82	1.25
PC (36:4) A	ME277484	0.69	1.01	1.00	1.30
PC (38:6) B	ME277493	0.73	0.93	0.98	1.36
PC 40:10;	ME277507	0.73	1.04	0.85	1.38
PC (40:6) A	ME277498	0.72	1.06	0.87	1.35
SM (d36:3)	ME277520	0.69	1.05	0.89	1.37
PC (30:0)	ME277474	0.70	1.01	0.88	1.41
PC 36:4;	ME277505	0.71	1.03	0.88	1.39
PC (39:6)	ME277496	0.71	1.03	0.87	1.39
PC (38:6) C	ME277494	0.81	0.97	0.83	1.40
PC (38:5) B	ME277491	0.77	1.02	0.84	1.36
Plasmenyl-PC 37:5;	ME277517	0.75	0.99	0.86	1.40
PC (38:6) A	ME277492	0.76	0.98	0.87	1.39
PC (38:5) A	ME277490	0.77	0.98	0.87	1.38
PC (40:8)	ME277500	0.77	0.98	0.87	1.38
PC (37:4)	ME277488	0.76	1.01	0.87	1.37
Plasmenyl-PC 36:4;	ME277516	0.76	0.99	0.89	1.36
PE (p-36:2) or PE (o-36:3)	ME277511	0.83	1.01	0.85	1.31
Plasmenyl-PC 38:6;	ME277518	0.85	1.01	0.84	1.30
PC (p-36:4) or PC (o-36:5)	ME277502	0.81	1.06	0.89	1.24
PC (34:2)	ME277478	0.80	1.03	0.90	1.27
PC (40:7)	ME277499	0.81	1.02	0.88	1.29
PC (40:5) A	ME277497	0.76	1.03	0.96	1.24
PC (31:0)	ME277476	0.78	1.06	0.92	1.23
PE (p-38:4) or PE (o-38:5)	ME277513	0.75	1.06	0.93	1.25
PC 37:5; PC(19:1/18:4);	ME277506	0.75	1.06	0.87	1.32
PC (31:1)	ME277477	0.72	1.09	0.90	1.29
PC (35:3)	ME277481	0.71	1.08	0.93	1.27
LPC (18:1)	ME277467	1.35	0.72	0.82	1.11
TG (54:5) A	ME277522	1.29	0.90	0.96	0.85
LPC (18:2)	ME277468	1.10	0.85	0.93	1.13
PE (38:6)	ME277510	1.02	0.89	0.85	1.24
PC (p-34:0) or PC (o-34:1)	ME277501	0.89	0.99	1.08	1.04
PE (34:2)	ME277509	0.90	0.92	1.04	1.15
DG (38:5)	ME277461	1.11	1.00	1.01	0.88
PC (p-42:3) or PC (o-42:4)	ME277504	1.01	1.08	0.89	1.02
PE (p-40:5) or PE (o-40:6)	ME277515	1.01	1.07	0.90	1.02
1_CE (22:1) iSTD	ME277447	1.00	1.01	0.99	1.00
1_CUDA (pos) iSTD	ME277450	0.98	1.00	1.02	1.00
1_iSTD iSTD SM (d18:1/17:0) iSTD	ME277453	1.01	0.97	0.99	1.03
1_MG (17:0/0:0/0:0) iSTD	ME277456	1.02	1.00	0.97	1.01
1_TG (17:0/17:1/17:0) d5 iSTD	ME277460	1.03	1.00	0.96	1.01
1_PE (17:0/17:0) iSTD	ME277458	1.05	0.97	0.97	1.01
1_DG (12:0/12:0/0:0) iSTD	ME277451	1.05	0.99	0.98	0.98
1_DG (18:1/2:0/0:0) iSTD	ME277452	1.03	0.99	0.98	1.00
1_Sphingosine (d17:1) iSTD	ME277459	1.02	0.98	0.99	1.01
1_PC (25:0) iSTD	ME277457	1.03	0.98	1.01	0.98
1_Ceramide C17 iSTD	ME277448	1.03	0.97	0.99	1.00
1_LPE (17:1) iSTD	ME277455	1.03	0.97	1.00	1.00
1_Cholesterol d7 iSTD	ME277449	1.04	0.98	0.99	0.99
1_LPC (17:0) iSTD	ME277454	1.04	0.97	1.00	0.99

Factors:

F1	ph treatment:High \| DO treatment:High
F2	ph treatment:High \| DO treatment:Low
F3	ph treatment:Low \| DO treatment:High
F4	ph treatment:Low \| DO treatment:Low

Data matrix